Document is current
Any future updates will be listed below
-
Authors
Hino, Kaori
Nishina, Tomohiro https://orcid.org/0000-0002-4073-3757
Koizumi, Mitsuhito
Marui, Kaori
Kokubu, Masahito
Numata, Yuki
Imamura, Yoshiki
Kanemitsu-Okada, Kozue
Otsuru, Toru
Kuroda, Taira
Ohno, Yoshinori
Asagi, Akinori
Miyata, Hideki
Yokota, Tomoyuki
Kumagi, Teru
Hyodo, Ichinosuke
Ikeda, Yoshio
Hiasa, Yoichi
- License Information
-
More Information
Article History
Received: 11 October 2024
Accepted: 29 January 2025
First Online: 27 February 2025
Declarations
:
: Tomohiro Nishina has received honorarium from Bristol Myers Squibb, Ono Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, Daiichi-Sankyo pharmaceutical companies, Astellas, and MSD. Ichinosuke Hyodo has served on advisory role for Ono Pharmaceutical, Asahi Kasei, Chugai, and Daiichi-Sankyo pharmaceutical companies. The other authors have no relevant financial or non-financial interests to disclose.
: The protocol was reviewed and approved by the Central Ethical Review Committee of the NHO Shikoku Cancer Center (number: 2021-59) in accordance with the Ethical Guidelines for Life Sciences and Medical Research Involving Human Subjects published on March 16, 2022 (). The study was initiated after receiving approval format from each participating hospital, and was conducted in accordance with the ethical principles of the Declaration of Helsinki. Informed consent was obtained from all patients to participate in this study.
